We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Johnson & Johnson (J&J), Merck and AstraZeneca are presenting positive phase 3 data supporting drugs for castration-resistant prostate cancer at this week’s meeting of the American Society of Clinical Oncology in San Francisco. Read More
Eli Lilly is picking up ImmunoGen’s camptothecin antibody-drug conjugate (ADC) platform in a $13 million deal that could eventually net ImmunoGen $1.7 billion. Read More
The Institute for Clinical and Economic Review (ICER) has weighed in on Eli Lilly’s type 2 diabetes drug candidate tirzepatide, saying payers should consider broadening coverage to GLP-1 RAs and SGLT-2 inhibitors like tirzepatide for diabetes type 2 patients with cardiovascular or renal disease — but only at a cost of $5,500 to $5,700 per year. Read More
Robert Califf has, at long last, been confirmed as the new commissioner of the FDA, in a close 50-to-46 Senate vote that contrasted with his easy 89-to-4 confirmation vote to the leadership role in 2016. Read More
In a cloture vote late Monday, the Senate voted 49 to 45 to limit floor debate on the nomination of Robert Califf to the role of Commissioner of the FDA. However, the Senate delayed the full-chamber vote on Califf’s possible confirmation until today at noon. Read More
The FDA doesn’t want any part of regulating the “sanitation tunnels” that have popped up in certain commercial settings as a response to the COVID-19 pandemic. Read More
The Federal Trade Commission (FTC) is likely to soon begin an examination into pharmacy benefit managers (PBMs), which could impact drugmakers. Read More
Eli Lilly and Roche/Genentech — both developers of antiamyloid antibodies for Alzheimer’s — have charged into the Aduhelm coverage war in defense of their own products. Read More